sunitinib mylan 12,5 mg cietās kapsulas
mylan ireland limited, ireland - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib mylan 50 mg cietās kapsulas
mylan ireland limited, ireland - sunitinibs - kapsula, cietā - 50 mg
sunitinib sandoz 25 mg cietās kapsulas
sandoz d.d., slovenia - sunitinibs - kapsula, cietā - 25 mg
sunitinib sandoz 50 mg cietās kapsulas
sandoz d.d., slovenia - sunitinibs - kapsula, cietā - 50 mg
sunitinib g.l. pharma 12,5 mg cietās kapsulas
g.l. pharma gmbh, austria - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib g.l. pharma 25 mg cietās kapsulas
g.l. pharma gmbh, austria - sunitinibs - kapsula, cietā - 25 mg
sunitinib g.l. pharma 50 mg cietās kapsulas
g.l. pharma gmbh, austria - sunitinibs - kapsula, cietā - 50 mg
sunitinib zentiva 12,5 mg cietās kapsulas
zentiva, k.s., czech republic - sunitinibs - kapsula, cietā - 12,5 mg
sunitinib zentiva 50 mg cietās kapsulas
zentiva, k.s., czech republic - sunitinibs - kapsula, cietā - 50 mg
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiski līdzekļi - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.